Loading clinical trials...
Loading clinical trials...
A Non-interventional, Multi-national, Multi-center Post-authorization Safety Study (PASS) to Assess the Long Term Safety and Tolerability of Odomzo (Sonidegib) Administered in Patients With Locally Advanced Cell Carcinoma (laBCC)
Conditions
Interventions
sonidegib
Locations
47
Germany
Katholisches Klinikum Bochum St. Josef-Hospital
Bochum, Germany
Elbe Kliniken Stade - Buxtehude GmbH
Buxtehude, Germany
Klinikum Darmstadt GmbH
Darmstadt, Germany
Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden
Dresden, Germany
Helios Klinikum
Erfurt, Germany
Universitaetsklinikum Essen
Essen, Germany
Start Date
March 11, 2019
Primary Completion Date
March 14, 2025
Completion Date
March 14, 2025
Last Updated
March 18, 2026
NCT03050268
NCT05969860
NCT05651828
NCT07144384
NCT07182240
NCT06623201
Lead Sponsor
Sun Pharmaceutical Industries Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions